stars 1 stars 2 stars 3

Inte:Ligand supports scientists worldwide with innovative approaches for early drug discovery research using computer-aided design solutions. Molecular designers in the pharmaceutical, cosmetic, nutrition, animal health and agro science industries use our solutions to design and identify novel bioactive molecules. We develop the most innovative and user friendly modeling software platforms and provide expert consulting to inspire the innovative process of designing molecules, filtering ideas, and de-risking candidates. Our off the shelf computer-aided design tools include LigandScout, ilib:Diverse, IL PharmDB and the IL Expert KNIME Extensions as well as validated 3D-chemical pharmacophore models for toxicity prediction and precomputed libraries for virtual screening. We provide all of the tools and knowledge you need for successful early drug discovery projects including training and validated workflows to help scientists design and identify bioactive molecules efficiently and productively.

Inte:Ligand GmbH Questions

The Inte:Ligand GmbH annual revenue was $4 million in 2026.

Sharon Bryant is the CEO of Inte:Ligand GmbH.

8 people are employed at Inte:Ligand GmbH.

The NAICS codes for Inte:Ligand GmbH are [54171, 541713, 5417, 54, 541].

The SIC codes for Inte:Ligand GmbH are [873, 87].

Top Inte:Ligand GmbH Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users